Imagion Biosystems Ltd. · ASX:IBX
Imagion Biosystems — Investor Presentation (June 2025)
13 slides from Imagion Biosystems's investor presentation, Jun 11, 2025
Slide 1: MRI Imaging Agents for Cancer
MRI Imaging A Breakthrough in Molecular Magnetic Resonance Imaging Agents for Cancer Detection Imagion Biosystems Limited ASX:IBX 1 IBX Investor Deck Copyright June 2025 | ImagionBiosystems.com
Slide 2: Forward Looking Statements
Forward Looking Statements This investor presentation (Presentation) has been prepared by Imagion Biosystems Limited (Imagion or the Company). This presentation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or o
Slide 3: Company & Leadership
Robert Proulx Executive Chairman Company & Leadership Robert has been CEO and Chairman of Imagion since 2015 bringing the technology and company from early proof of concept to clinical stage. • Scientifically proven, novel-platform addressing multi billion dollar market. Ward Detwiler • Strong clini
Slide 4: Over 50% of cancers are diagnosed at late stage
5- YEAR SURVIVAL RATE Over 50% of cancers are DEPENDING ON EARLY OR LATE diagnosed at late stage1. DIAGNOSIS: Prostate Cancer Ovarian Cancer CANCER DIAGNOSTICS - $100B MARKET 7% CAGR $30,000 28% 27% $26,044 $25,000 100% 92% $20,136 Millions $20,000 $15,541 Early Late Early Late $15,000 Breast Cancer
Slide 5: The Unmet Need
The Unmet Need Getting to certainty takes too long. Conventional Imaging provides anatomical context but is not specific and can only identify a region of interest. Screening Imaging Biopsy Indicates risk, but non- Identify “suspicious Painful, complicated, error prone and diagnostic. Requires lesio
Slide 6: How MagSense molecular MRI works
Pre-Dose Post-Dose MagSense® nanoparticles enable molecular imaging by producing an How MagSense® molecular identifiable change in image contrast MRI works when cancer cells are present MagSense particles are coated with unique Pre-Dose Post-Dose targeting moiety and administered before MRI MagSense
Slide 7: MagSense mMRI Technology Transforming molecular imaging
Clinical Pipeline MagSense® mMRI Technology Transforming molecular imaging HER2+ Breast Cancer $500M TAM Ready for Phase 2 Specific Provides molecular confirmation of cancer, not just “suspicion”. MRI-based Detection Compatible across 50k+ MRI Safer Prostate Cancer scanners in use globally. $1B TAM
Slide 8: mMRI Enables AI Detection
Unique quantitative signature allows for Artificial Intelligence mMRI Enables AI Detection and Machine Learning algorithms for automated detection. Existing iron-based AI diagnostics already show proof of concept. https://archive.ismrm.org/2021/3258.html 8 IBX Investor Deck Copyright June 2025 | Ima
Slide 9: Investment Rationale
Investment Rationale Costs by Category Associated with SOC versus MagSense per 1,000 patients $5.0 Complications Large Markets with an Unmet Medical Need $4.5 $0.3 $0.2 • Global cancer incidence to rise 77% by 2050 with screening & diagnostic $4.0 SLNB Costs in Millions (USD) imaging costs growing a
Slide 10: Pathway to Value Creation
Pathway to Value Creation Completed 2025 2026 2027 Key Next Steps HER2+ IND File IND and initiate Breast Phase 1 Phase 2 Phase 3 Phase 2 study for HER2 Cancer Dose and Image Protocol Optimization imaging agent IND Ovarian Cancer Pre-Clinical IND-enabling Phase 1 Phase 2 Complete IND Human Safety ena
Slide 11: Strategic Partnering
Comparable Transactions Strategic Partnering Incumbents continue making attractive deals for differentiated clinical-stage assets Strategic Target Value AUD Year Notes Strategic investment. Part of $70M $18M 2024 AUD financing transaction. $35M revenue at time of transaction. $310M 2024 Breast cance
Slide 12: Capital Needs and Use of Funds
Capital Needs and Use of Funds Bridge Round Use of Funds HER2 IND Submission & (End Q2 ‘25) Study Preparation 9% G&A Expenses • IND approval of HER2 Phase 2 18% • CRO engagement • Imaging protocol optimization • Clinical lot manufacturing • Strategic partner engagement Prostate IND Enabling 14% Clin
Slide 13: info@imagionbio.com | ASX:IBX
info@imagionbio.com | ASX:IBX 13 IBX Investor Deck Copyright June 2025 | ImagionBiosystems.com
Imagion Biosystems — Investor Presentation (June 2025) on 6ix